BR112019006955A2 - métodos de controle da dor usando dispositivos de distribuição transdérmica de dexmedetomidina - Google Patents
métodos de controle da dor usando dispositivos de distribuição transdérmica de dexmedetomidinaInfo
- Publication number
- BR112019006955A2 BR112019006955A2 BR112019006955A BR112019006955A BR112019006955A2 BR 112019006955 A2 BR112019006955 A2 BR 112019006955A2 BR 112019006955 A BR112019006955 A BR 112019006955A BR 112019006955 A BR112019006955 A BR 112019006955A BR 112019006955 A2 BR112019006955 A2 BR 112019006955A2
- Authority
- BR
- Brazil
- Prior art keywords
- subject
- transdermal delivery
- dexmedetomidine
- delivery device
- methods
- Prior art date
Links
- HRLIOXLXPOHXTA-NSHDSACASA-N dexmedetomidine Chemical compound C1([C@@H](C)C=2C(=C(C)C=CC=2)C)=CN=C[N]1 HRLIOXLXPOHXTA-NSHDSACASA-N 0.000 title abstract 6
- 229960004253 dexmedetomidine Drugs 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 6
- 230000037317 transdermal delivery Effects 0.000 title abstract 5
- 230000000887 hydrating effect Effects 0.000 abstract 2
- 239000012530 fluid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
os aspectos da invenção incluem métodos de controle da dor em um sujeito através da aplicação de um dispositivo de distribuição transdérmica contendo uma composição de dexmedetomidina formulada para fornecer uma quantidade eficaz de dexmedetomidina para aliviar a dor a um sujeito. na prática dos métodos de acordo com certas modalidades, um dispositivo de distribuição transdérmica que tem uma composição de dexmedetomidina é aplicado a um indivíduo e é mantido em contato com o indivíduo de uma maneira suficiente para administrar uma quantidade da dexmedetomidina eficaz no controle da dor no sujeito. em algumas modalidades, os métodos incluem a hidratação do sujeito, tal como pela administração de uma composição de fluido de hidratação ao sujeito. os métodos, de acordo com certas modalidades, também podem incluir a coadministração de um opioide ao sujeito. também é fornecido um dispositivo de distribuição transdérmica configurado para distribuir dexmedetomidina o suficiente para praticar os métodos da presente invenção, assim como kits contendo o dispositivo de distribuição transdérmica.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662415248P | 2016-10-31 | 2016-10-31 | |
| US201762547582P | 2017-08-18 | 2017-08-18 | |
| PCT/US2017/059357 WO2018081812A2 (en) | 2016-10-31 | 2017-10-31 | Methods of managing pain using dexmedetomidine transdermal delivery devices |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019006955A2 true BR112019006955A2 (pt) | 2019-07-02 |
Family
ID=62020311
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019006955A BR112019006955A2 (pt) | 2016-10-31 | 2017-10-31 | métodos de controle da dor usando dispositivos de distribuição transdérmica de dexmedetomidina |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20180117012A1 (pt) |
| EP (1) | EP3532038A4 (pt) |
| JP (2) | JP2019534288A (pt) |
| KR (3) | KR20210113439A (pt) |
| CN (1) | CN110022865A (pt) |
| BR (1) | BR112019006955A2 (pt) |
| CA (1) | CA3038354C (pt) |
| RU (1) | RU2723761C1 (pt) |
| TW (1) | TWI764951B (pt) |
| WO (1) | WO2018081812A2 (pt) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6868698B2 (ja) | 2016-12-31 | 2021-05-12 | バイオエクセル セラピューティクス，インコーポレイテッド | 激越の治療のための舌下デクスメデトミジンの使用 |
| US20210251914A1 (en) * | 2018-06-20 | 2021-08-19 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
| MX2020014000A (es) | 2018-06-27 | 2021-06-15 | Bioxcel Therapeutics Inc | Formulaciones en lámina que contienen dexmedetomidina y métodos para producirlas. |
| CN113710238A (zh) * | 2019-04-17 | 2021-11-26 | Lts勒曼治疗系统股份公司 | 透皮治疗系统 |
| BR112022000992A2 (pt) | 2019-07-19 | 2022-06-14 | Arx Llc | Regimes de tratamento de dexmedetomidina não sedantes |
| WO2021026375A1 (en) * | 2019-08-07 | 2021-02-11 | Alkermes, Inc. | Fused bicyclic compounds for the treatment of pain |
| WO2021026378A1 (en) * | 2019-08-07 | 2021-02-11 | Alkermes, Inc. | Indole compounds for the treatment of pain |
| WO2021026380A1 (en) * | 2019-08-07 | 2021-02-11 | Alkermes, Inc. | Phenyltriazole compounds for the treatment of pain |
| WO2021026377A1 (en) * | 2019-08-07 | 2021-02-11 | Alkermes, Inc. | Lactam-containing compounds for the treatment of pain |
| CN111281850A (zh) * | 2020-03-14 | 2020-06-16 | 周琛 | 止痛药物组合物及其用途 |
| CN117582424A (zh) * | 2022-08-17 | 2024-02-23 | 宜昌人福药业有限责任公司 | 右美托咪定经皮组合物、透皮贴剂及其制备方法和应用 |
| US11806334B1 (en) | 2023-01-12 | 2023-11-07 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2215206B (en) * | 1988-02-29 | 1991-07-03 | Farmos Oy | 4-substituted imidazole derivatives useful in perioperative care |
| US5124157A (en) * | 1989-08-18 | 1992-06-23 | Cygnus Therapeutic Systems | Method and device for administering dexmedetomidine transdermally |
| CA2727015A1 (en) * | 2008-06-04 | 2009-12-10 | Coda Therapeutics, Inc. | Treatment of pain with gap junction modulation compounds |
| CA2786598A1 (en) * | 2010-01-08 | 2011-07-14 | Recro Pharma, Inc. | Topical transdermal dexmedetomidine compositions and methods of use thereof |
| US20130096170A1 (en) * | 2011-10-14 | 2013-04-18 | Hospira, Inc. | Methods of treating pediatric patients using dexmedetomidine |
| KR101827980B1 (ko) * | 2013-10-07 | 2018-02-13 | 테이코쿠 팔마 유에스에이, 인코포레이티드 | 덱스메데토미딘 경피 전달 장치 및 이의 사용 방법 |
| KR101881791B1 (ko) * | 2013-10-07 | 2018-07-25 | 테이코쿠 팔마 유에스에이, 인코포레이티드 | 비진정성 덱스메데토미딘 경피 조성물을 사용하여 금단 증후군을 치료하기 위한 방법 및 조성물 |
| JP6188934B2 (ja) * | 2013-10-07 | 2017-08-30 | テイコク ファーマ ユーエスエー インコーポレーテッド | デクスメデトミジン経皮組成物を含む疼痛管理用方法及び組成物 |
| ES2847936T3 (es) * | 2013-10-07 | 2021-08-04 | Teikoku Pharma Usa Inc | Métodos y composiciones para el suministro transdérmico de una cantidad no sedante de dexmedetomidina |
| JP6469587B2 (ja) * | 2013-12-18 | 2019-02-13 | 丸石製薬株式会社 | 含水型貼付剤 |
-
2017
- 2017-10-31 TW TW106137654A patent/TWI764951B/zh active
- 2017-10-31 WO PCT/US2017/059357 patent/WO2018081812A2/en unknown
- 2017-10-31 KR KR1020217028734A patent/KR20210113439A/ko not_active IP Right Cessation
- 2017-10-31 KR KR1020197014883A patent/KR20190060007A/ko active Application Filing
- 2017-10-31 RU RU2019109873A patent/RU2723761C1/ru active
- 2017-10-31 JP JP2019522825A patent/JP2019534288A/ja active Pending
- 2017-10-31 EP EP17865069.3A patent/EP3532038A4/en active Pending
- 2017-10-31 CN CN201780072175.5A patent/CN110022865A/zh active Pending
- 2017-10-31 US US15/799,602 patent/US20180117012A1/en active Pending
- 2017-10-31 KR KR1020237010276A patent/KR20230048156A/ko not_active Application Discontinuation
- 2017-10-31 CA CA3038354A patent/CA3038354C/en active Active
- 2017-10-31 BR BR112019006955A patent/BR112019006955A2/pt not_active Application Discontinuation
-
2022
- 2022-12-23 JP JP2022206760A patent/JP2023036825A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023036825A (ja) | 2023-03-14 |
| CN110022865A (zh) | 2019-07-16 |
| RU2723761C1 (ru) | 2020-06-17 |
| CA3038354A1 (en) | 2018-05-03 |
| CA3038354C (en) | 2021-08-17 |
| JP2019534288A (ja) | 2019-11-28 |
| TWI764951B (zh) | 2022-05-21 |
| TW201817419A (zh) | 2018-05-16 |
| KR20210113439A (ko) | 2021-09-15 |
| KR20230048156A (ko) | 2023-04-10 |
| WO2018081812A3 (en) | 2019-01-17 |
| WO2018081812A2 (en) | 2018-05-03 |
| US20180117012A1 (en) | 2018-05-03 |
| EP3532038A4 (en) | 2020-06-03 |
| KR20190060007A (ko) | 2019-05-31 |
| EP3532038A2 (en) | 2019-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019006955A2 (pt) | métodos de controle da dor usando dispositivos de distribuição transdérmica de dexmedetomidina | |
| BR112020017090A8 (pt) | Imunoterapias relacionadas com microbioma | |
| BR112016014481A2 (pt) | tratamento de câncer utilizando combinações de inibidores de erk e raf | |
| BR112016014410A2 (pt) | terapia de combinação com vacina de neoantígeno | |
| BR112017003546A2 (pt) | amidas heterocíclicas como inibidores de rip1 quinase como medicamentos | |
| CL2015002736A1 (es) | Composición farmacéutica de clorhidrato de s-ketamina. | |
| BR112015027282A8 (pt) | formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet | |
| BR112016027041A8 (pt) | combinações farmacêuticas para tratamento do câncer | |
| BR112016002171A2 (pt) | método, composição estéril e injetável e método para preparar uma composição estéril e injetável | |
| BR112019008431A2 (pt) | aplicação de (s)-norcetamina e sal da mesma como fármaco | |
| BR112015022514A2 (pt) | composições que compreendem selênio e uso das mesmas para o tratamento e prevenção de doença ou condições associadas à disfunção mitocondrial | |
| BR112016006848A2 (pt) | métodos e composições para distribuição transdérmica de uma quantidade não sedativa de dexmedetomidina | |
| BR112018015718A2 (pt) | utilização de estimuladores de sgc para o tratamento de esteato-hepatite não alcoólica (nash) | |
| BR112017003433A2 (pt) | inibidores espirocíclicos de catepsina c | |
| BR112018011700A2 (pt) | ?moduladores de canais de kv3 para tratar dor? | |
| MX2017006938A (es) | Terapia de combinacion para el tratamiento de cancer. | |
| BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
| BR112017009798A2 (pt) | profármacos de hgh poliméricos | |
| BR112015022650A8 (pt) | inibidores de quinase induzível por sal macrocíclico. | |
| BR112016017897A8 (pt) | uso de composto de carboxamida heterocíclica de diamino no tratamento de câncer relacionado ao axl, composição farmacêutica e combinação | |
| BR112016027435A2 (pt) | formulação inovadora de meloxicam | |
| BR112015022846A2 (pt) | uso de um composto para tratar ou prevenir um angioedema mediado pelo receptor b2 da bradicinina e formulação compreendendo o mesmo | |
| BR112017008721A2 (pt) | formulação líquida injetável, composição de liberação controlada, e, métodos para entrega prolongada de buprenorfina, para formação de uma composição de liberação controlada e para tratamento ou profilaxia de um sujeito animal humano ou não humano. | |
| BR112015022982A2 (pt) | inibidores macrocíclicos de rip2 quinase | |
| BR112016013754A2 (pt) | Recaptação de serotonina-norepinefrina inibidores (irsns) e combinações dos ligantes do receptor sigma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |